Symbols

CRNX

Crinetics·NASDAQ

--(--)

CRNX fundamentals

CRNX Q4 2025 Earnings

Crinetics (CRNX) released its earnings on Feb 26, 2026: revenue was 6.16M (YoY --), beat estimates; EPS was -1.29 (YoY -46.59%), beat estimates.

Revenue / YoY

6.16M

EPS / YoY

-1.29

-46.59%

Report date

Feb 26, 2026

CRNX Earnings Call Summary for Q4,2025

Breakout Year Achievements: PALSONIFY launched with 200+ Q4 enrollments, 50% commercial reimbursement, and top payer formulary wins.
Pipeline Momentum: Atumelnant Phase II/III ADCS study starts in H1 2026; CRN09682 enters Phase I/II for SST2-expressing tumors.
Financial Strength: $1.4 billion cash post-January 2026 offering; 2026 operating expenses guided at $600-650 million.
Innovative Study Design: ADCS trial features adaptive dosing and proactive glucocorticoid replacement to address historical Cushing's treatment challenges, PALSONIFY's rapid onset and symptom control drive prescriber confidence.

Earnings

EPS

Revenue

Revenue & Expenses

CRNX has released its 2025 Q4 earnings report, with revenue of 6.16M, reflecting a YoY change of NaN%, and net profit of -122.81M, showing a YoY change of -52.39%. The Sankey diagram below clearly presents CRNX's revenue sources and cost distribution.

Key Indicators

Crinetics (CRNX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Crinetics (CRNX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Crinetics (CRNX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Crinetics (CRNX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown